newsfilter
← Latest News
Business Wire·

Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update

CTP-543 THRIVE-AA1 Phase 3 Trial in Patients with Moderate to Severe Alopecia Areata Fully Enrolled with Topline Data Expected Second Quarter of 2022 CTP-543 THRIVE-AA2 Phase 3 Trial in Patients with Moderate to Severe Alopecia Areata Progressing wit